Browsing by Subject
Ara mostrant els elements 1-20 d 26
-
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
(Lippincott Williams & Wilkins, 2022-12-01) -
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers
(Nature Portfolio, 2022-11-07) -
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
(American Society of Clinical Oncology, 2023-10-20) -
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
(Korean Society of Gynecologic Oncology & Colposcopy, 2021-11) -
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
(American Society of Clinical Oncology, 2023-05-01) -
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy
(Nature Portfolio, 2022-01-27) -
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
(American Association for Cancer Research, 2022-10-15) -
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
(American Association for Cancer Research, 2023-09-15) -
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
(BMC, 2021-05-26) -
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
(American Society of Clinical Oncology, 2023-01-20)